Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis.
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease associated with accelerated atherosclerosis and increased risk of cardiovascular (CV) disease. AS patients also display a high prevalence of features clustered under the name of metabolic syndrome (MeS). Anti-TNF- α therapy was found to be effective to treat AS patients by suppressing inflammation and also improving endothelial function. Previously, it was demonstrated that a short infusion of anti-TNF- α monoclonal antibodyinfliximab induced a rapid and dramatic reduction in serum insulin levels and insulin resistance along with a rapid improvement of insulin sensitivity in nondiabetic AS patients. The role of adipokines, MeS-related biomarkers and biomarkers of endothelial cell activation and inflammation seem to be relevant in different chronic inflammatory diseases. However, its implication in AS has not been fully established. Therefore, in this review we summarize the recent advances in the study of the involvement of these molecules in CV disease or MeS in AS. The assessment of adipokines and biomarkers of endothelial cell activation and MeS may be of potential relevance in the stratification of the CV risk of patients with AS.
Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, 39011 Santander, Spain.
Fernanda
0000-0003-3612-1448
F
Genre
Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, 39011 Santander, Spain.
Raquel
R
López-Mejías
Rheumatology Division, Hospital Lucus Augusti, 27003 Lugo, Spain.
José A
JA
Miranda-Filloy
Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, 39011 Santander, Spain.
Begoña
B
Ubilla
Oncology Division, Hospital del Bierzo, 24411 Ponferrada, León, Spain.
Beatriz
B
Carnero-López
Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, 39011 Santander, Spain.
Ricardo
R
Blanco
Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, 39011 Santander, Spain.
Trinitario
T
Pina
Cardiology Division, Hospital Lucus Augusti, 27003 Lugo, Spain.
Carlos
C
González-Juanatey
Computational Biology, School of Medicine, University of Cantabria, IDIVAL, and CIBER Epidemiología y Salud Pública (CIBERESP), 39011 Santander, Spain.
Javier
J
Llorca
Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, 39011 Santander, Spain.
Miguel A
MA
González-Gay
D054392:Adipokines / Q000097:blood*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D004730:Endothelium, Vascular / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D024821:Metabolic Syndrome / Q000097:blood* / Q000188:drug therapy / Q000209:etiology; D012307:Risk Factors; D013167:Spondylitis, Ankylosing / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000097:blood
D054392:Adipokines; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015415:Biomarkers; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab